Patient-Focused Drug Development Conference

March 9, 2015 Hyatt Regency Hotel in Bethesda, MD

Number of Attendees: 162 total, 110 Industry, 18 Academia, 34 FDA,

P.I. – Dr. Eleanor Perfetto, UMB

Co P.I.’s- Elisabeth Oehrlein, UMB, Theresa Mullin FDA, Ashley Slagle FDA, Pujita Vaidya FDA, Sara Eggers FDA

The M-CERSI Conference on Patient-Focused Drug Development took place on March 9, 2015 at the Bethesda Hyatt with 228 registrants and 162 in attendance. The speakers represented various stakeholder groups such as: patients and patient advocates, regulatory, academia, the biopharmaceutical industry, and payers. The attendees also represented various stakeholder groups including academia, industry, regulatory, patients and patient advocacy groups, among others. Topics discussed included ongoing FDA initiatives on engaging patients as part of the regulatory process, patient perspectives on the added value of incorporating their voices into drug development and ongoing activities that patient advocacy groups are pursuing to have their voices heard, and finally the industry perspective on the importance of patient engagement. The conference ended with a panel discussion with all aforementioned stakeholder groups represented, along with a representative from the Patient-Centered Outcomes Research Institute (PCORI) and the payer community. According to evaluations, the conference was very well received by attendees and participants reported they gained important knowledge about initiatives within patient-focused drug development.